Biblio

Author Title [ Type

] Year

Filters: Author is Fleury, Isabelle [Clear All Filters]

Journal Article

Lemieux C, Ahmad I, Bambace NM, Bernard L, Cohen S, Delisle J-S, Fleury I, Kiss T, Mollica L, Roy D-C, et al. Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Lymphoma Patients. Biol Blood Marrow Transplant. 2019.

Lachance S, Bourguignon A, Boisjoly J-A, Bouchard P, Ahmad I, Bambace N, Bernard L, Cohen S, Delisle J-S, Fleury I, et al. Impact of Implementing a Bendamustine-based Conditioning Regimen on outcomes of Autologous Stem Cell Transplant in Lymphoma while Novel Cellular Therapies Emerge. Transplant Cell Ther. 2022.

Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021.

Maziarz RT, Waller EK, Jaeger U, Fleury I, McGuirk J, Holte H, Jaglowski S, Schuster SJ, Bishop MR, Westin JR, et al. Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4(4):629-637.

Nowakowski GS, Yoon DHyun, Mondello P, Joffe E, Peters A, Fleury I, Greil R, Ku M, Marks R, Kim K, et al. RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large . Ann Hematol. 2023.